Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Tax Provisions (2016 - 2025)

Enanta Pharmaceuticals filings provide 12 years of Tax Provisions readings, the most recent being $24000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 105.77% to $24000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.3 million, a 433.83% decrease, with the full-year FY2025 number at -$1.8 million, down 1018.13% from a year prior.
  • Tax Provisions hit $24000.0 in Q4 2025 for Enanta Pharmaceuticals, up from -$80000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $48.5 million in Q3 2021 to a low of -$9.4 million in Q2 2021.
  • Median Tax Provisions over the past 5 years was -$36000.0 (2021), compared with a mean of $2.5 million.
  • The widest YoY moves for Tax Provisions: up 1044.3% in 2023, down 1729.41% in 2023.
  • Enanta Pharmaceuticals' Tax Provisions stood at -$36000.0 in 2021, then increased by 5.56% to -$34000.0 in 2022, then plummeted by 1729.41% to -$622000.0 in 2023, then soared by 33.12% to -$416000.0 in 2024, then soared by 105.77% to $24000.0 in 2025.
  • The last three reported values for Tax Provisions were $24000.0 (Q4 2025), -$80000.0 (Q3 2025), and $29000.0 (Q2 2025) per Business Quant data.